These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 21509439)

  • 1. Homoharringtonine as a backbone drug for the treatment of newly diagnosed pediatric acute myeloid leukemia: a report from a single institution in China.
    Tang J; Liu Y; Chen J; Xue H; Pan C; Gu L
    Int J Hematol; 2011 May; 93(5):610-617. PubMed ID: 21509439
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of low-dose cytarabine, homoharringtonine and granulocyte colony-stimulating factor priming regimen on patients with advanced myelodysplastic syndrome or acute myeloid leukemia transformed from myelodysplastic syndrome.
    Wu L; Li X; Su J; Chang C; He Q; Zhang X; Xu L; Song L; Pu Q
    Leuk Lymphoma; 2009 Sep; 50(9):1461-7. PubMed ID: 19672772
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Homoharringtonine-based induction regimens for patients with de-novo acute myeloid leukaemia: a multicentre, open-label, randomised, controlled phase 3 trial.
    Jin J; Wang JX; Chen FF; Wu DP; Hu J; Zhou JF; Hu JD; Wang JM; Li JY; Huang XJ; Ma J; Ji CY; Xu XP; Yu K; Ren HY; Zhou YH; Tong Y; Lou YJ; Ni WM; Tong HY; Wang HF; Mi YC; Du X; Chen BA; Shen Y; Chen Z; Chen SJ
    Lancet Oncol; 2013 Jun; 14(7):599-608. PubMed ID: 23664707
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A homoharringtonine-based induction regimen for the treatment of elderly patients with acute myeloid leukemia: a single center experience from China.
    Wang J; Lü S; Yang J; Song X; Chen L; Huang C; Hou J; Zhang W
    J Hematol Oncol; 2009 Jul; 2():32. PubMed ID: 19642997
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Homoharringtonine in combination with cytarabine for patients with acute myelogenous leukemia.
    Feldman E; Arlin Z; Ahmed T; Mittelman A; Puccio C; Chun H; Cook P; Baskind P
    Leukemia; 1992 Nov; 6(11):1189-91. PubMed ID: 1434803
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Efficacy of induction chemotherapy for patients with high-risk myelodysplastic syndrome (MDS) or MDS-transformed acute myeloid leukemia with CHG regimen and its comparison with regimen GAG and HA].
    Su JY; Chang CK; Zhang X; Zhou LY; Song LQ; Xu L; Wu LY; He Q; Li X
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Apr; 17(2):459-63. PubMed ID: 19379588
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The efficacy and safety of a homoharringtonine-based protocol for children with acute myeloid leukemia: A retrospective study in China.
    Tang Y; Luo C; Shen S; Xue H; Pan C; Hu W; Chen X; Cai J; Chen J; Tang J
    Pediatr Hematol Oncol; 2021 Mar; 38(2):97-107. PubMed ID: 33016804
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Homoharringtonine in patients with myelodysplastic syndrome (MDS) and MDS evolving to acute myeloid leukemia.
    Feldman EJ; Seiter KP; Ahmed T; Baskind P; Arlin ZA
    Leukemia; 1996 Jan; 10(1):40-2. PubMed ID: 8558935
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low dose of homoharringtonine and cytarabine combined with granulocyte colony-stimulating factor priming on the outcome of relapsed or refractory acute myeloid leukemia.
    Gu LF; Zhang WG; Wang FX; Cao XM; Chen YX; He AL; Liu J; Ma XR
    J Cancer Res Clin Oncol; 2011 Jun; 137(6):997-1003. PubMed ID: 21152934
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness of homoharringtonine (omacetaxine mepesuccinate) for treatment of acute myeloid leukemia: a meta-analysis of Chinese studies.
    Kantarjian H; O'Brien S; Jabbour E; Barnes G; Pathak A; Cortes J
    Clin Lymphoma Myeloma Leuk; 2015 Jan; 15(1):13-21. PubMed ID: 25458084
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Clinical study on combination of homoharringtonine, Ara-C and idarubicin induction for treatment of newly diagnosed acute myeloid leukemia patients].
    Qin TJ; Xu ZF; Fang LW; Zhang HL; Zhang Y; Wang JZ; Pan LJ; Hu NB; Xiao ZJ
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Oct; 19(5):1277-82. PubMed ID: 22040988
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-dose homoharringtonine versus standard-dose daunorubicin is effective and safe as induction and post-induction chemotherapy for elderly patients with acute myeloid leukemia: a multicenter experience from China.
    Huang BT; Zeng QC; Yu J; Liu XL; Xiao Z; Zhu HQ
    Med Oncol; 2012 Mar; 29(1):251-9. PubMed ID: 21258877
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Homoharringtonine is safe and effective for patients with acute myelogenous leukemia.
    Feldman E; Arlin Z; Ahmed T; Mittelman A; Puccio C; Chun H; Cook P; Baskind P
    Leukemia; 1992 Nov; 6(11):1185-8. PubMed ID: 1434802
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Homoharringtonine is a safe and effective substitute for anthracyclines in children younger than 2 years old with acute myeloid leukemia.
    Chen X; Tang Y; Chen J; Chen R; Gu L; Xue H; Pan C; Tang J; Shen S
    Front Med; 2019 Jun; 13(3):378-387. PubMed ID: 30635781
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Homoharringtonine in newly diagnosed acute promyelocytic leukemia treatment: a prospective, randomized controlled trial].
    Wang Y; Liu BC; Wei H; Lin D; Zhou CL; Liu KQ; Li W; Wei SN; Wang JY; Gong BF; Zhang GJ; Zhao XL; Liu YT; Gong XY; Li Y; Gu RX; Mi YC; Wang JX
    Zhonghua Xue Ye Xue Za Zhi; 2016 Mar; 37(3):183-8. PubMed ID: 27033753
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Efficacy of venetoclax-based induction regimen in newly diagnosed pediatric acute myeloid leukemia].
    Wen XJ; Lu Y; Huang PL; Zhang YY; Yu JJ; Qi PJ; Huang Q; Yang J; Liu HQ; Hou B; Wang LY; Li HQ; Lin W; Wu Y; Zhang RD; Li J; Luo D; Li YN; Liu M; Zhao ZW; Liu Y; Zheng HY
    Zhonghua Yi Xue Za Zhi; 2024 Jul; 104(27):2513-2520. PubMed ID: 38978375
    [No Abstract]   [Full Text] [Related]  

  • 17. A homoharringtonine-based regimen for childhood acute myelogenous leukemia.
    Tang J; Xue H; Pan C; Chen J; Gu L; Zhao H
    Med Pediatr Oncol; 2003 Jul; 41(1):70-2. PubMed ID: 12764750
    [No Abstract]   [Full Text] [Related]  

  • 18. Effect of granulocyte colony-stimulating factor priming combined with low-dose cytarabine and homoharringtonine in higher risk myelodysplastic syndrome patients.
    Wang FX; Zhang WG; He AL; Cao XM; Chen YX; Zhao WH; Yang Y; Wang JL; Zhang PY; Gu LF
    Leuk Res; 2016 Sep; 48():57-61. PubMed ID: 27497340
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bortezomib added to daunorubicin and cytarabine during induction therapy and to intermediate-dose cytarabine for consolidation in patients with previously untreated acute myeloid leukemia age 60 to 75 years: CALGB (Alliance) study 10502.
    Attar EC; Johnson JL; Amrein PC; Lozanski G; Wadleigh M; DeAngelo DJ; Kolitz JE; Powell BL; Voorhees P; Wang ES; Blum W; Stone RM; Marcucci G; Bloomfield CD; Moser B; Larson RA
    J Clin Oncol; 2013 Mar; 31(7):923-9. PubMed ID: 23129738
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low dose of homoharringtonine and cytarabine-based priming induction regimens for patients with
    Wang F; Xu W; Liu L; Ren X; Liu P; Zheng L; Zhang H; Zhang S; Xu Y; Guo Z
    Hematology; 2021 Dec; 26(1):1040-1045. PubMed ID: 34895093
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.